e-Edition
Obituaries
In Loving Memory
Magazines
Subscribe
Login to Comment
Register
jobs
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Life
Commentary
Contact
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
23.02
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
23.02
Bid (Size)
18.50 (1,000)
Ask (Size)
23.39 (100)
Prev. Close
23.02
Today's Range
23.02 - 23.02
52wk Range
18.41 - 43.22
Shares Outstanding
70,814,462
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline
March 02, 2026
From
Berger Montague
Via
GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
March 01, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Performance
YTD
-2.5%
-2.5%
1 Month
-7.0%
-7.0%
3 Month
-31.0%
-31.0%
6 Month
-28.1%
-28.1%
1 Year
-44.2%
-44.2%
More News
Read More
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
March 01, 2026
Via
TheNewswire.com
Topics
Fraud
Lawsuit
RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors With Losses to Contact the Firm
February 28, 2026
Via
NewMediaWire
Topics
Fraud
Lawsuit
RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors With Losses to Contact the Firm
February 28, 2026
Via
TheNewswire.com
Topics
Fraud
Lawsuit
RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors With Losses to Contact the Firm
February 27, 2026
Via
NewMediaWire
Topics
Fraud
Lawsuit
RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors With Losses to Contact the Firm
February 27, 2026
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
February 25, 2026
From
SkyMedia, LLC
Via
GlobeNewswire
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026
February 25, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
February 25, 2026
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
February 25, 2026
Via
NewMediaWire
Topics
Fraud
Lawsuit
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
February 24, 2026
From
Kahn Swick & Foti, LLC
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE
February 24, 2026
From
Pomerantz LLP
Via
GlobeNewswire
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
February 24, 2026
From
Schall Law
Via
GlobeNewswire
Ultragenyx to Participate at Investor Conferences in March
February 23, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Deadline in Securities Fraud Class Action Lawsuit
February 23, 2026
Via
NewMediaWire
Topics
Fraud
Lawsuit
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Deadline in Securities Fraud Class Action Lawsuit
February 23, 2026
Via
TheNewswire.com
Topics
Fraud
Lawsuit
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder
↗
February 23, 2026
Via
Stocktwits
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
February 23, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action Lawsuit Filed; April 6, 2026, Lead Plaintiff Deadline
February 22, 2026
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action Lawsuit Filed; April 6, 2026, Lead Plaintiff Deadline
February 22, 2026
Via
NewMediaWire
Topics
Fraud
Lawsuit
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline
February 21, 2026
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline
February 21, 2026
Via
NewMediaWire
Topics
Fraud
Lawsuit
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
February 20, 2026
From
Schall Law
Via
GlobeNewswire
Frequently Asked Questions
Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?
Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.
What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?
Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?
The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market
What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?
The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 23.02
When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?
The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 03/02/26 04:00 PM ET
What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?
The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.63B
How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?
Ultragenyx Pharmaceutical Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
wpDiscuz
Insert